RxDoctor Payments Data

Kevin Campbell, MD

Cardiovascular Disease · Melbourne, FLNPI 1770581134

Payments from drug & device makers

$98,331in general payments, 2019–2025

Across 110 payments — averaging $893.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Avertix Medical, Inc$72K
  • Biotronik Inc.$24K
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$2K
  • Medtronic$420
  • Impulse Dynamics (USA) Inc.$169
  • Boehringer Ingelheim$99
  • plus $319 from 10 others

What the payments were for

  • Consulting fees$71,58873%
  • Speaking & faculty fees$7,7658%
  • Travel & lodging$13,07613%
  • Food & beverage$5,4025%
  • Charitable contribution$5001%

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$98,331 in reported general payments places this provider in the 85th percentile of 1,740 cardiovascular disease providers in Florida.

See all cardiovascular disease providers in Florida

Medicare billing

Part B allowed, 2024
$416,260
Medicare patients
1,188
Services billed
5,333

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XareltoRivaroxaban115$142,161
EliquisApixaban120$125,227
EntrestoSacubitril/Valsartan50$74,155
Repatha SureclickEvolocumab18$24,147
Dabigatran EtexilateDabigatran Etexilate Mesylate51$18,559
Metoprolol Succinate386$6,830
Losartan Potassium511$6,525
Rosuvastatin Calcium220$4,162
Chlorthalidone176$3,970
Diltiazem 24hr Er (Cd)Diltiazem Hcl34$3,091
Flecainide Acetate55$3,042
SotalolSotalol Hcl64$2,102
Ranolazine ErRanolazine22$1,783
Amlodipine Besylate177$1,762
Carvedilol141$1,726

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonXarelto$95$142,161115 claims
PfizerEliquis$18$125,227120 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,740 cardiovascular disease providers in Florida.

Other cardiovascular disease in Melbourne

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →